Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans

NCT ID: NCT05120635

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-01

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anxiety disorders such as post-traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD) affect a large number of individuals with a significant portion of patients failing to improve with current treatments.

The purpose of this study is to understand the brain mechanisms that produce fear and anxiety in humans. To accomplish this goal, we will measure the brain activity along with the heart rate and skin perspiration of patients while they are completing tasks on a computer. Some of the tasks will also use a virtual reality headset and transport the patient in a video game-like environment. These tasks will expose the participants to various levels of fear-provoking images. Participants with responsive neurostimulation (RNS) implants will be enrolled under Pro00117931 at Duke, but their results for fear and anxiety tasks will be reported under NCT05120635.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fear GAD Emotional Memory PTSD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EMU Participants

Subjects participating in the study at the Epilepsy Monitoring Unity (EMU).

Group Type OTHER

Deep Brain Stimulation

Intervention Type DEVICE

Deep brain stimulation will be used

Virtual and augmented reality tasks

Intervention Type BEHAVIORAL

Virtual and augmented reality tasks will be used.

RNS Participants

Subjects with RNS implants.

Group Type OTHER

Deep Brain Stimulation

Intervention Type DEVICE

Deep brain stimulation will be used

Virtual and augmented reality tasks

Intervention Type BEHAVIORAL

Virtual and augmented reality tasks will be used.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deep Brain Stimulation

Deep brain stimulation will be used

Intervention Type DEVICE

Virtual and augmented reality tasks

Virtual and augmented reality tasks will be used.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older
* Has undergone acute depth or chronic responsive neurostimulation (RNS) electrode placement
* Willing to provide informed consent and participate in the study
* Ability to read and write English fluently

Exclusion Criteria

* Unwilling to provide informed consent
* Has not undergone acute depth or chronic responsive neurostimulation (RNS) electrode placement
* Pregnant women
* Participants with active psychosis
* Participants with suicidal ideation
* Participants with substance abuse issues
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health (NIH)

NIH

Sponsor Role collaborator

VA Greater Los Angeles Healthcare System

FED

Sponsor Role collaborator

NeuroPace

INDUSTRY

Sponsor Role collaborator

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

Duke University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nanthia Suthana, PhD

Role: PRINCIPAL_INVESTIGATOR

Duke Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California Los Angeles

Los Angeles, California, United States

Site Status RECRUITING

Duke University Health System

Durham, North Carolina, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gabriela Vilchez

Role: CONTACT

9196812577

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sonja Hiller

Role: primary

919-681-2577

Gabriela Vilchez

Role: primary

919-681-2577

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01MH124761

Identifier Type: NIH

Identifier Source: secondary_id

View Link

Pro00117931

Identifier Type: OTHER

Identifier Source: secondary_id

PRO00118015

Identifier Type: -

Identifier Source: org_study_id